Sartorius Stedim Biotech financials
Sartorius Stedim Biotech
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
52990006IVXY7GCSSR39 Financial statements
(EUR, as reported — unscaled; 101 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Cost of sales | €1.62B | €1.57B |
| Gross profit | €1.35B | €1.21B |
| Other income | €56.6M | €37.0M |
| Distribution costs | €479.0M | €479.8M |
| Administrative expenses | €182.3M | €168.7M |
| Operating profit (EBIT) | €525.7M | €370.6M |
| Net finance income / (cost) | -€152.5M | -€151.3M |
| Finance costs | €192.7M | €196.7M |
| Profit before tax | €373.2M | €219.2M |
| Income tax expense | €107.3M | €40.7M |
| Profit for the year | €266.0M | €178.5M |
| — attributable to owners | €265.6M | €175.1M |
| — attributable to NCI | €300.0K | €3.4M |
| Total comprehensive income | €161.8M | €227.4M |
| Per share | ||
| Basic EPS | €2.73 | €1.81 |
| Diluted EPS | €2.73 | €1.81 |
| Cash flow statement | ||
| Net cash from operating activities | €692.2M | €815.1M |
| Net cash from investing activities | -€397.7M | -€340.0M |
| Net cash from financing activities | -€542.8M | €84.9M |
| Dividends paid | €68.0M | €68.0M |
| Proceeds from borrowings | €13.3M | €17.3M |
| Net change in cash | -€248.3M | €560.0M |
| Balance sheet | ||
| Total assets | €7.98B | €8.26B |
| Non-current assets | €6.54B | €6.52B |
| Intangible assets & goodwill | €2.88B | €2.91B |
| Current assets | €1.44B | €1.74B |
| Inventories | €690.9M | €684.9M |
| Cash & equivalents | €426.1M | €678.9M |
| Total equity | €4.13B | €4.02B |
| — attributable to owners | €4.09B | €3.99B |
| Non-controlling interests | €35.6M | €37.2M |
| Non-current liabilities | €2.45B | €3.29B |
| Long-term borrowings | €1.87B | €2.68B |
| Lease liabilities (non-current) | €151.2M | €120.6M |
| Current liabilities | €1.41B | €938.8M |
| Lease liabilities (current) | €23.4M | €25.0M |
| Deferred tax liabilities | €375.6M | €358.2M |
| Derived metrics | ||
| Operating margin | 17.7% | 13.3% |
| Net margin | 9.0% | 6.4% |
| Return on equity | 6.4% | 4.4% |
| Cash conversion ratio | 2.60× | 4.57× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€46.4M | €207.6M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €42.9M | €38.3M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €318.1M | €301.7M |
| Adjustments For Finance Income Cost | -€152.5M | -€151.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€21.4M | €2.8M |
| Adjustments For Provisions | -€500.0K | €2.3M |
| Capital Reserve | €1.42B | €1.42B |
| Comprehensive Income Attributable To Noncontrolling Interests | -€700.0K | €2.7M |
| Comprehensive Income Attributable To Owners of Parent | €162.5M | €224.8M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €557.3M | €39.5M |
| Current Contract Liabilities | €167.6M | €216.1M |
| Current Provisions For Employee Benefits | €99.1M | €88.2M |
| Current Tax Assets Current | €31.5M | €33.8M |
| Current Tax Liabilities Current | €82.0M | €123.2M |
| Deferred Tax Assets | €75.2M | €63.2M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €67.1M | €67.1M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €900.0K | €900.0K |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €67.1M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.69 | — |
| Dividends Recognised As Distributions To Owners Per Share | €0.69 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€4.5M | €2.3M |
| Equity and Liabilities | €7.98B | €8.26B |
| Finance Income | €40.2M | €45.4M |
| Gains Losses On Cash Flow Hedges Before Tax | €44.2M | -€13.8M |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | €9.7M | -€5.2M |
| Income Tax Relating To Components of Other Comprehensive Income | €10.4M | -€5.7M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €700.0K | -€600.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €149.1M | €133.5M |
| Increase Decrease Through Transfers and Other Changes Equity | €200.0K | -€500.0K |
| Increase Decrease Through Treasury Share Transactions | €200.0K | -€1.9M |
| Intangible Assets Other Than Goodwill | €1.54B | €1.63B |
| Interest Paid Classified As Financing Activities | €153.6M | €176.9M |
| Interest Received Classified As Operating Activities | €17.5M | €22.9M |
| Issue of Equity | €0 | €1.19B |
| Issued Capital | €19.5M | €19.5M |
| Noncurrent Provisions For Employee Benefits | €32.6M | €33.6M |
| Other Adjustments For Noncash Items | €5.5M | €2.3M |
| Other Comprehensive Income | -€104.1M | €48.9M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | €32.4M | -€17.2M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -€127.6M | €63.3M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €1.5M | -€2.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€127.6M | €63.3M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€105.0M | €51.3M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €900.0K | -€2.3M |
| Other Current Financial Assets | €23.6M | €11.7M |
| Other Current Financial Liabilities | €141.7M | €71.9M |
| Other Current Nonfinancial Assets | €76.3M | €65.8M |
| Other Current Nonfinancial Liabilities | €47.0M | €47.6M |
| Other Expense By Function | €81.8M | €80.6M |
| Other Longterm Provisions | €16.8M | €15.1M |
| Other Noncurrent Financial Liabilities | €2.2M | €81.9M |
| Other Noncurrent Nonfinancial Assets | €3.6M | €3.3M |
| Other Shortterm Provisions | €16.3M | €17.4M |
| Proceeds From Issuing Shares | €0 | €1.19B |
| Property Plant and Equipment Including Rightofuse Assets | €2.02B | €1.89B |
| Purchase of Financial Instruments Classified As Investing Activities | €4.4M | €100.0K |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | €11.8M | €3.4M |
| Research and Development Expense | €133.1M | €144.1M |
| Revenue From Contracts With Customers | €2.97B | €2.78B |
| Trade and Other Current Payables To Trade Suppliers | €277.8M | €310.0M |
Methodology
Every line item above is a fact tagged in Sartorius Stedim Biotech's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.